Filing summary
Issuer mismatch: The request identifies Nexttrip, Inc., but the supplied filing is Sigma Labs, Inc.’s Form 10-K. The summary below covers Sigma Labs. This is an annual report for the fiscal year ended December 31, 2016, not a standalone fourth-quarter report. Financial statements received an unqualified audit opinion.
Business context and reporting period
Sigma Labs develops PrintRite3D, hardware and software for real-time quality assurance of metal additive manufacturing (3D printing), and provides engineering consulting and contract metal-printing services. The company remained at an early commercialization stage; most 2016 revenue came from consulting and other contracts rather than recurring software licensing.
Key financial metrics
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $966,422 | $1,234,810 |
| Gross profit / gross margin | $737,520 / 76.4% | $1,020,806 / 82.7% |
| Operating expenses | $3,251,486 | $2,717,650 |
| Net loss | $2,196,834 | $1,696,282 |
| Loss per share, basic and diluted | $0.70 | $0.54 |
| Cash used in operating activities | $1,962,314 | $1,260,463 |
Revenue comprised $893,791 from PrintRite3D-enabled engineering consulting and $72,631 from contract manufacturing in 2016. In 2015, the respective amounts were $1,164,709 and $70,101. The filing does not provide a clear standalone quarterly Q4 financial breakdown.
At December 31, 2016, cash was $398,391, current assets were $909,924, current liabilities were $799,125, and working capital was positive $110,799. Total liabilities were $892,331 and total stockholders’ equity was $977,038. The company reported an accumulated deficit of $9,760,954. There was no credit line.
Material changes versus prior year
- Revenue declined 21.7%, principally because the GE Aviation-led America Makes project and DARPA Phase II provided fewer months of revenue in 2016 than in 2015.
- Gross profit fell 27.7%, and gross margin contracted by about 6.3 percentage points.
- Net loss increased by $500,552. General and administrative expense rose $507,144 and payroll expense rose $441,134; lower stock-based compensation and R&D costs, together with $317,132 of other income, partly offset those increases.
- Cash declined from $1,539,809 to $398,391. Operating cash use increased, while the company raised $900,000 gross from an October 2016 secured convertible-note financing.
- R&D expense decreased to $92,992 from $330,554. Management attributed the increase in payroll partly to hiring seven additional employees.
Outlook, risks and unusual items
- Management expected commercialization, consulting contracts and contract manufacturing to support future revenue, but the company said current revenue was insufficient to fund operations and it expected operating and commercialization costs to rise. It anticipated fewer losses in 2017, while also expecting higher salaries and related costs; this is not formal financial guidance.
- The filing gives differing liquidity horizons: MD&A says available funds and expected receipts were believed sufficient for operating expenses through 2017, while the risk-factor discussion says February 2017 offering proceeds, cash and anticipated revenue were expected to fund operations until at least January 2019. Both are management estimates, not guarantees.
- After year-end, the company closed a public offering that generated approximately $5.8 million gross and $5.25 million net. It also moved to Nasdaq and completed a 1-for-2 reverse stock split. These events were not reflected in the December 31, 2016 balance sheet.
- The October 2016 notes had $1 million principal, generated $900,000 gross proceeds, carry 10% annual interest and mature October 17, 2017. The notes are secured and include conversion terms; the filing also describes a 15% prepayment penalty. The balance sheet reports notes payable net of discount of $561,834, while the note disclosure describes a $920,114 carrying balance and a $1 million effective payoff amount. Reconcile these figures and the repayment terms.
- Customer concentration is substantial: two customers accounted for 40.93% and 29.97% of 2016 revenue. One customer represented 75.74% of year-end receivables.
- Other key risks include continued losses and operating cash burn, reliance on additional financing, uncertain adoption and commercialization of the technology, competition from substantially larger firms, dependence on key personnel, and exposure to government-contract compliance and customer contract terms. No legal proceedings were reported at filing time.
- Post-year-end commercial agreements and announced opportunities included OEM and customer relationships, but anticipated contract values and future revenue were not assured. The company also lent Morf3D $500,000 in March 2017 at 7%, secured by certain Morf3D assets and convertible at Sigma’s option into 10% of Morf3D, subject to repayment provisions.
Important facts for investors to verify
- Confirm the issuer: the supplied document is Sigma Labs, Inc., not Nexttrip, Inc.
- Reconcile the convertible-note principal, reported carrying values, discounts, interest and prepayment obligations; assess maturity and dilution risk.
- Review post-offering cash, subsequent cash burn and the basis for management’s differing liquidity estimates.
- Assess whether revenue can diversify beyond consulting and the two major customers, and whether announced agreements convert into recurring, collected revenue.
- Evaluate customer receivable collection, contract concentration, and the commercial progress and funding needs of PrintRite3D and contract manufacturing.